2425.T

The company maintains a strong liquidity position, with a current ratio of 3.7, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to 1,843,945,000 JPY, significantly exceeding its total liabilities of 1,195,933,000 JPY, which suggests a conservative capital structure. The company's return on equity of 12.79% and return on assets of 9.08% indicate strong profitability relative to its equity and asset base.

The company's profitability is further underscored by its operating income of 492,466,000 JPY and net income of 374,023,000 JPY, which reflect efficient cost management and revenue generation. These figures are in line with the industry's preferred metrics, emphasizing the importance of maintaining high gross and operating margins. The company's debt-to-equity ratio of 0.02 indicates minimal reliance on debt financing, which is a favorable position in the healthcare sector.

The company's revenue is concentrated in a single segment, as no specific segments are disclosed, and there is no geographic breakdown provided in the available data. This lack of diversification could pose a risk if the primary market experiences a downturn. The company's growth trajectory is supported by its recent financial performance, with a revenue of 9,862,197,000 JPY and a net income of 374,023,000 JPY. Analysts have noted the last actual revenue of 9,862,200,000 JPY, which aligns with the company's reported figures.

The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of dilution potential and the low debt levels suggest a stable capital structure. The company's recent financial filings and transcripts do not indicate any significant events that would impact its operations or financial health.